Phosphoregulation of the RNA-binding Protein Hu Antigen R (HuR) by Cdk5 Affects Centrosome Function

Por Filippova, Natalia, Yang, Xiuhua, King, Peter, Nabors, L. Burt
Publicado em 2012

Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme

Por Reardon, David A, Nabors, L Burt, Stupp, Roger, Mikkelsen, Tom
Publicado em 2008

Pilot study to explore the accuracy of current prediction equations in assessing energy needs of patients with newly-diagnosed glioblastoma multiforme

Por Little, Rebecca B., Oster, Robert A., Darnell, Betty E., Demark-Wahnefried, Wendy, Nabors, L. Burt
Publicado no Nutr Cancer (2016)

AT-24 PHASE 1/2 TRIAL OF BEVACIZUMAB PLUS TPI 287, A NOVEL BRAIN PENETRABLE ANTI-MICROTUBULE AGENT, FOR THE TREATMENT OF RECURRENT GLIOBLASTOMA

Por Goldlust, Samuel, Nabors, L. Burt, Duic, J. Paul, Conrad, Charles, Silberman, Sandra, Singer, Samuel, Farmer, George
Publicado em 2014

Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Ast...

Por Patel, Daxa M., Foreman, Paul M., Nabors, L. Burt, Riley, Kristen O., Gillespie, G. Yancey, Markert, James M.
Publicado no Hum Gene Ther Clin Dev (2016)

THE RNA-BINDING PROTEIN HUR PROMOTES GLIOMA GROWTH AND TREATMENT RESISTANCE

Por Filippova, Natalia, Yang, Xiuhua, Wang, Yimin, Gillespie, G Yancey, Langford, Cathy, King, Peter H., Wheeler, Crystal, Nabors, L. Burt
Publicado em 2011

The ELAV RNA-stability factor HuR binds the 5′-untranslated region of the human IGF-IR transcript and differentially represses cap-dependent and IRES-mediated translation

Por Meng, Zheng, King, Peter H., Nabors, L. Burt, Jackson, Nateka L., Chen, Ching-Yi, Emanuel, Peter D., Blume, Scott W.
Publicado em 2005

Rationally designed pharmacogenomic treatment using concurrent capecitabine and radiotherapy for glioblastoma; gene expression profiles associated with outcome

Por Grunda, Jessica M., Fiveash, John, Palmer, Cheryl A., Cantor, Alan, Fathallah-Shaykh, Hassan M., Nabors, L. Burt, Johnson, Martin R.
Publicado em 2010

ATNT-08 CB-017: A PHASE 1/2 TRIAL OF BEVACIZUMAB PLUS TPI 287, A NOVEL BRAIN PENETRABLE ANTI-MICROTUBULE AGENT, IN PATIENTS WITH RECURRENT GLIOBLASTOMA NAÏVE TO ANTI-ANGIOGENIC THE...

Por Goldlust, Samuel, Nabors, L. Burt, Duic, J. Paul, Mohile, Nimish, Benkers, Tara, Hsu, Sigmund, Silberman, Sandra, Singer, Samuel, Farmer, George
Publicado no Neuro Oncol (2015)

Sex Hormone-Dependent Attenuation of EAE in a Transgenic Mouse with Astrocytic Expression of the RNA Regulator HuR

Por Wheeler, Crystal, Nabors, L. Burt, Barnum, Scott, Yang, Xiuhua, Hu, Xianzhen, Schoeb, Trenton, Chen, Dongquan, Ardelt, Anise A., King, Peter H.
Publicado em 2012

Complementary therapy and survival in glioblastoma

Por Mulpur, Bhageeradh H., Nabors, L. Burt, Thompson, Reid C., Olson, Jeffrey J., LaRocca, Renato V., Thompson, Zachary, Egan, Kathleen M.
Publicado no Neurooncol Pract (2015)

Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells

Por Dixon, Dan A., Tolley, Neal D., King, Peter H., Nabors, L. Burt, McIntyre, Thomas M., Zimmerman, Guy A., Prescott, Stephen M.
Publicado em 2001

Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas

Por Grossman, Stuart A., Carson, Kathryn A., Phuphanich, Surasak, Batchelor, Tracy, Peereboom, David, Nabors, L. Burt, Lesser, Glenn, Hausheer, Fredrick, Supko, Jeffrey G.
Publicado em 2008

Characterization and immunotherapeutic potential of γδ T-cells in patients with glioblastoma

Por Bryant, Nichole L., Suarez-Cuervo, Catalina, Gillespie, G. Yancey, Markert, James M., Nabors, L. Burt, Meleth, Sreelatha, Lopez, Richard D., Lamb, Lawrence S.
Publicado em 2009

Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma

Por Phuphanich, Surasak, Supko, Jeffrey G., Carson, Kathryn A., Grossman, Stuart A., Nabors, L. Burt, Mikkelsen, Tom, Lesser, Glenn, Rosenfeld, Steve, Desideri, Serena, Olson, Jeffrey J.
Publicado em 2010

ATCT-15 CB-018: A PHASE 2 TRIAL OF BEVACIZUMAB PLUS TPI 287, A NOVEL BRAIN PENETRABLE ANTI-MICROTUBULE AGENT, IN PATIENTS WITH RECURRENT GLIOBLASTOMA FOLLOWING PROGRESSION ON ANTI-...

Por Goldlust, Samuel, Nabors, L. Burt, Sahebjam, Solmaz, Hsu, Sigmund, Mohile, Nimish, Benkers, Tara, Giglio, Pierre, Raizer, Jeffrey, Silberman, Sandra, Kumthekar, Priya, Singer, Samuel, Farmer, George
Publicado no Neuro Oncol (2015)

NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme

Por Peereboom, David M., Ahluwalia, Manmeet S., Ye, Xiaobu, Supko, Jeffrey G., Hilderbrand, Sarah L., Phuphanich, Surasak, Nabors, L. Burt, Rosenfeld, Myrna R., Mikkelsen, Tom, Grossman, Stuart A.
Publicado em 2013

Mutant Tristetraprolin: a Potent Inhibitor of Malignant Glioma Cell Growth

Por Suswam, Esther A., Shacka, John J., Walker, Kiera, Lu, Liang, Li, Xuelin, Si, Ying, Zhang, Xiaowen, Zheng, Lei, Nabors, L. Burt, Cao, Heping, King, Peter H.
Publicado em 2013

ATNT-17 EVALUATION OF THE SAFETY AND BENEFIT OF PHASE I ONCOLOGY TRIALS FOR PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM TUMORS

Por Nayak, Lakshmi, Gounder, Mrinal, Sahebjam, Solmaz, Muzikansky, Alona, Sanchez, Armando, Desideri, Serena, Ye, Xiaobu, Ivy, Percy, Nabors, L. Burt, Prados, Michael, Grossman, Stuart, DeAngelis, Lisa, Wen, Patrick
Publicado no Neuro Oncol (2015)

A Safety Run-in and Randomized Phase II Study of Cilengitide Combined with Chemoradiation for Newly Diagnosed Glioblastoma (NABTT 0306)

Por Nabors, L. Burt, Mikkelsen, Tom, Hegi, Monika E., Ye, Xiaubu, Batchelor, Tracy, Lesser, Glenn, Peereboom, David, Rosenfeld, Myrna R., Olsen, Jeff, Brem, Steve, Fisher, Joy D., Grossman, Stuart A.
Publicado em 2012